Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (1767)	3/15/1999 6:14:00 PM
From: Craig Sutton	Respond to of 2205

Wow, excellent summary ! Caught on to a couple of those earlier but thanks for the time saver. I've been with this stock for some time now (too long in most opinions) and put it on the back burner, way back - as it hurts to look at it. BUT... these prices are pretty darn good for a buyer looking to make a few big ones over the next year or so. Thanks, CraigS

To: Rick Strange who wrote (1767)	3/15/1999 10:28:00 PM
From: Marshall Teitelbaum	Read Replies (3) \| Respond to of 2205

Rick, The May 5 orthopod meeting has the hint of a "wildcard" here. If they announce significant enough news, it may actually be enough to get the fundamental component of the technical movement rolling some, especially with a near term follow up of the past discussed cardiovascular partnership...especially if with good terms. Of course, to have the really big inning, dermagraft needs to come through. I also wonder what the odds of a company signing a cardiovascular partnership would be without in-depth due diligence into the company, including the odds of the near term survival product being effective (or not). Guess the proof will be in the pudding....ie actually signing the deal and later(or earlier, although unlikely) announcement of trial data for dermagraft being positive(obviously the best case scenario). It will be interesting to see whether the Securities Analyst meeting will get much going. I doubt it will do except put ATIS on the watch list going into the second quarter for institutional purposes. Hope all is well everyone. Rick, thanks for posting the info. Marshall